Nasdaq · Healthcare
10x Genomics, Inc. (TXG)
As-reported financials and recent SEC filings for 10x Genomics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$642.8M
Net income
$-43.5M
Net margin
-6.8%
Diluted EPS
$-0.35
ROE
-5.5%
P/E (TTM)
—
Market cap
$4.67B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $642.8M | $610.8M | $618.7M | $516.4M | $490.5M |
| Gross profit | $443.9M | $414.5M | $409.3M | $396.0M | $416.4M |
| Operating income | $-61.0M | $-194.6M | $-265.3M | $-167.9M | $-52.3M |
| Net income | $-43.5M | $-182.6M | $-255.1M | $-166.0M | $-58.2M |
| Diluted EPS | $-0.35 | $-1.52 | $-2.18 | $-1.46 | $-0.53 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-24
View on EDGAR →42026-06-18
View on EDGAR →1442026-06-16
View on EDGAR →8-K2026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →Go deeper on TXG
Search 10x Genomics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.